RATIONAL PHARMACOTHERAPY BASED ON PHARMACOECONOMIC DATA AUDIT: PRINCIPLES AND APPLICATION IN BULGARIA
https://doi.org/10.20996/1819-6446-2014-10-4-402-405
Abstract
The theoretical foundations of the application of pharmacoeconomic evaluations of pharmacotherapies in order to improve their economic efficiency and support the process of taking decisions on their payment from public funds are examined. An algorithm is presented for the pharmacoeconomic audit, which is applicable for assessing the objectivity and reliability of the proposed pharmacoeconomic data from pharmaceutical manufacturers in the application process for inclusion in the positive list of medicines in Bulgaria and the reimbursement of economically rational pharmacotherapies from the public health fund.
About the Author
T. Vekov
Medical University of Pleven
Bulgaria
Sv. Kliment Ohridski str. 1, Pleven, 5800 Bulgaria
Bulgaria
Sv. Kliment Ohridski str. 1, Pleven, 5800 Bulgaria
References
1. Leopold C., Vagler S., Mantel-Teenwisse A. Differences in external price referencing in Europe – A descriptive overview. Health Policy 2012; 104(1): 50-60.
2. Gandjour A. Reference Pricing and Price Negotiations for Innovative New Drugs, Viable Policies in the Long Term? Pharmaco Economics 2013; 31(1): 11-5.
3. Grieve R., Sadique M. Statistical methods for cost-effectiveness analyses that use observational data: A critical appraisal tool and review of current practice. Health Economics 2013; 22(4): 486-500.
4. Dakin H., Wordsworth S. Cost-minimisation analysis vs. cost-effectiveness analysis. Health Economics 2013; 22(1): 22-34.
5. Norman R., Hall J., Street D., Viney R. Efficiency and equity: A stated preference approach, Health Economics 2013; 22(5): 568-81.
6. Weinstein M. Economic assessments of medical practices and technologies. Medical Decision-Making 1981; 4: 309-30.
7. Gold M., Siegel J., Russell L., Weinstein M. Cost-effectiveness in Health and Medicine. NY: Oxford University Press;1996.
8. Espin J., Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. European Commission, 2007. Available at: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/study_pricing_2007/andalusian_school_public_health_report_pricing_2007_en.pdf. Accessed by 20.06.2014.
9. Cabrales A., Jimenez-Martin S. The determinants of pricing in pharmaceuticals: Are US prices really so high? Health Economics 2013; 11: 1377-97.
10. Forster M., Pertile P. Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective. Health Economics 2013; 12: 1507-14.
11. Longworth L., Youn J., Bojke L. et al. When Does NICE Recommend the Use of Health Technologies Within a Program of Evidence Development? Pharmaco Economics 2013; 31(2): 137-50.
12. Torrance G. Measurement of health state utilities for economic appraisal. J Health Economics 1986; 5:1-30.
Review
For citations:
Vekov T. RATIONAL PHARMACOTHERAPY BASED ON PHARMACOECONOMIC DATA AUDIT: PRINCIPLES AND APPLICATION IN BULGARIA. Rational Pharmacotherapy in Cardiology. 2014;10(4):402-405. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-4-402-405
Views:
886
Email this article 